3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
8
Melanoma
8
Pancreatic Neoplasms
7
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
5
Uterine Cervical Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor
2
Sarcoma
2
Recurrence
2
Liver Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Advanced Solid Tumor
2
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Salivary Gland Neoplasms
1
Refractory or Recurrent Solid Tumor
1
Pelvic Neoplasms
1
Ovarian Neoplasms
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Mesothelioma, Malignant
1
Interventions
Gemcitabine
3
Capecitabine
3
tivozanib
2
pembrolizumab
2
Oxaliplatin
2
Cisplatin
2
trametinib
1
tislelizumab
1
spartalizumab
1
silmitasertib
1
pertuzumab
1
olutasidenib
1
devimistat
1
atezolizumab
1
Sorafenib
1
Ritonavir
1
Pemetrexed
1
Nivolumab
1
Itraconazole
1
Ipilimumab
1
Epirubicin
1
Carboplatin
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Bile Duct Neoplasms
×
spartalizumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts